Last mentioned: Mar 25, 2026
Black Market Surge
Current reports highlight the critical risk of black market drugs due to the blurring of medicine and cosmetics.
Regulatory Pivot
Regulators begin targeting social media platforms for 'cosmetic' marketing of prescription drugs.
Counterfeit Warning
The WHO issues a global alert regarding falsified semaglutide products found in legitimate supply chains.
Global Shortages Begin
Novo Nordisk and Eli Lilly report significant supply constraints for semaglutide and tirzepatide.
The rapid transition of GLP-1 weight loss medications from clinical treatments to 'lifestyle' products is creating a regulatory vacuum exploited by black market actors. Health authorities warn that the blurring of medicine and cosmetics is driving a surge in counterfeit drugs and unmonitored usage.
India's pharmaceutical sector has launched a massive rollout of affordable versions of popular weight-loss medications, targeting the global dominance of high-priced GLP-1 agonists. This move threatens the premium pricing models of Western pharmaceutical giants while significantly expanding patient access in price-sensitive emerging markets.